Immune scores in colorectal cancer: Where are we?

David Malka, Astrid Lièvre, Thierry André, Julien Taïeb, Michel Ducreux, Frédéric Bibeau

Research output: Contribution to journalReview articlepeer-review

51 Scopus citations


There is growing evidence that the immune system may prevent the occurrence, growth and metastatic diffusion of colorectal cancer (CRC). The role played by the adaptive immune response at the tumour site is critical in the balance between tumour invasion and defence against cancer. Recent data have shown that the evaluation of this immune response may help to define the prognosis and possibly the treatment of localised CRC as well as metastatic CRC. Tumour infiltrates with T cells (CD3+), cytotoxic T cells (CD8+) and memory T cells (CD45RO+) are the immune parameters most consistently and strongly associated with good clinical outcome in CRC. Several scoring systems have been developed, including the Immunoscore®, based on the immunohistochemical determination with a digital image analysis system of the density of CD3+ and CD8+ lymphocytes in the centre and the invasive margin of the tumour. This review will focus on the different immunoscoring systems developed in CRC, their performance, their limitations and their potential for improving patients' care in the future.

Original languageEnglish
Pages (from-to)105-118
Number of pages14
JournalEuropean Journal of Cancer
StatePublished - Nov 2020
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2020 Elsevier Ltd


  • Colorectal cancer
  • Immune score
  • Immunity
  • Prognosis


Dive into the research topics of 'Immune scores in colorectal cancer: Where are we?'. Together they form a unique fingerprint.

Cite this